medical

Maxim Sees Major Upside In These Biotech Stocks – Athersys, Inc …

Related ATHXMorning Market GainersWhy Investors Are Watching Athersys Ahead Of Stem Cell DataIn a recent report, analysts at Maxim Group discussed the biotechnology sector and gave their outlook for five names in the space. Here’s a rundown of what they had to say.Athersys, Inc. (NASDAQ: ATHX)Analysts believe that Athersys may have found a “sweet spot” for stroke treatment timing, as […]

The Best Biotech ETF Isn't Always The Biggest

View photo.Biotechnology ETFs have leapt out of the gate in 2015 with another strong spurt of momentum that has catapulted them to the top of sector rankings. The unequivocal asset leader in this category is the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB), which has more than $8 billion under management.IBB has gained more than 12 percent so far this […]

Receptos CEO: Building for the long term – CNBC.com

Who can beat the ‘superbug’?
A new antibiotic-resistant “superbug” may have contributed to the deaths of 2 patients at Ronald Reagan-UCLA Medical Center. What companies may be on track to combat the deadly virus, with CNBC’s Meg Tirrell.
A year ago, Receptos was a billion-dollar company looking to compete with drugmakers sometimes a hundred times its size, in therapeutic areas already served […]

Biotech Stocks Are Apparently Immune to Risks of the Day: New Highs Again …Update

Update 1/27 After the Close Amgen Beats
Amgen, Inc (AMGN) fourth quarter earnings and sales beat estimates on strong sales of Enbrel, an arthritis drug.Revenue for Q4 was $5,33B a 6% increase over Q4 2013, The stock was up slightly after hours to $159.40. Sales growth was also driven by Kyprolis and Prolia. The P/S is still a modest 6.12 and […]

How to play the JPMorgan health conference

Thinking about buying into biotech ahead of the JPMorgan Health Care Conference? History says the best play is to buy the day before the meeting starts and hold until the end.The JPMorgan conference, from Monday to Thursday, is the health industry’s biggest annual event, setting the agenda for the year. Sentiment out of the conference can dominate the first half […]

Biotechs Avoid Harsh Sell-Off: Many Stocks in the Green

About Raynovich Rod
Rod Raynovich is an experienced biotech investor an analyst with a focus in vaccines, tools, IVD’s and biopharmaceuticals. Prior to starting Raygent, he was a former technology transfer officer for UCLA and he has held various executive positions in the biotech and pharmaceutical industry, including senior positions at NASDAQ listed medical device companies. He was a founder and […]

Prana Biotechnology joins other biotech companies in the doldrums

” itemprop=”image”/>Share prices of biotech stocks are hitting the wall at the rate of one a week, with Prana Biotechnology the latest company to suffer. Its shares were dumped on Tuesday after poor research results.The shares dived 74 per cent, hitting the pockets of some of the country’s wealthiest families and wiping out a remarkable surge that had seen its […]

Happy New Year 2015!

About Raynovich Rod
Rod Raynovich is an experienced biotech investor an analyst with a focus in vaccines, tools, IVD’s and biopharmaceuticals. Prior to starting Raygent, he was a former technology transfer officer for UCLA and he has held various executive positions in the biotech and pharmaceutical industry, including senior positions at NASDAQ listed medical device companies. He was a founder and […]

Biotechs stall as risk appetite fades

Brian RobinsWhat a difference a year makes. The downturn in mining stocks from 2013 saw hot money flow into the biotech sector. But after some spectacular research failures, sentiment soured, leaving the sector firmly in the shadows for much of 2014 so that even the surge in biotech stocks globally bypassed the local players.Alchemia, QRx Pharma and Prana were all […]

3 stocks to buy in a market crash

NEW YORKThe stock market has gotten a bit more finicky over the past week, and that begs the question of whether or not investors could be in for a rocky start to 2015.If so, investors should be putting together their plans for handling a market drop now, rather than risk reacting poorly when the tape is tumbling. With that in […]